Videos & Activities
Outreach, increasing awareness about end-stage liver disease, and informing patients, relatives, and the general public about A-TANGO’s research aims and results is one of our key objectives. While the European Association for the Study of the Liver (EASL) is a medical association dedicated to pursuing excellence in liver research, improving the treatment of liver disorders in clinical practice, and providing education to anyone interested in hepatology, the European Liver Patients’ Association (ELPA) is an organisation by patients for patients, dedicated to promoting the interests of people with liver disease. Both EASL and ELPA are active consortium members and support A-TANGO with events, videos, and activities targeted towards hepatologists, trainees, and patients suffering from liver disease all over Europe.
Introducing G-TAK, a novel combinatorial therapy for cirrhosis & ACLF (by Dr. med. Cornelius Engelmann)
In this laymen-oriented webinar, the clinical study supervisor, Dr. med. Cornelius Engelmann (Charité), explains the different stages of liver cirrhosis and how this novel combinatorial treatment, G-TAK, may increase the survival rate of patients suffering from decompensated cirrhosis or ACLF. The video is a recording of a presentation given at an online patient event that was jointly organised by ELPA and EF CLIF and took place on 9 June 2021.
Interviews from ILC 2022
Patient representatives from the European Liver Patients’ Association (ELPA) and consortium members ask Dr. med. Cornelius Engelmann (Charité), the supervisor of our clinical G-TAK study, questions about alcohol consumption and alcoholic hepatitis, about the symptoms and potential biomarkers of acute-on-chronic liver failure (ACLF), and about gender balance in research. The interviews were conducted during the International Liver Congress (#ILC2022) in London, United Kingdom, on 24 June 2022.
Will I develop alcoholic hepatitis if I drink alcohol?
What is multiorgan failure? What organ stops working first? Do I need all organs?
If I develop acute-on-chronic liver failure, will it go away if I stop drinking?
What is a biomarker in acute-on-chronic liver failure? Can I measure it myself?
What about gender balance in the project? Is ACLF different in men versus women?
Here, Dr. Nina Donner (A-TANGO work package 7 leader) from concentris, inquires about the importance of gender balance within the project and whether liver disease, specifically ACLF, differs between men and women. Dr. Cornelius Engelmann (Charité) answers.